Elamipretide shielded mouse ovaries from cisplatin damage via the Nrf2 pathway

The mitochondria-targeted peptide SS-31 (elamipretide) — recently FDA-approved as FORZINITY for Barth syndrome — may have a second act in reproductive medicine. In a new Frontiers in Pharmacology study, three weeks of SS-31 treatment restored ovarian function in mice with cisplatin-induced premature ovarian failure: larger ovaries, more follicles at multiple developmental stages, normalized hormones, and repaired mitochondrial membrane potential in oocytes and granulosa cells.

How the experiment ran

Researchers induced premature ovarian failure with cisplatin (2 mg/kg for 7 days), then treated with SS-31 at 10 mg/kg for three weeks. The peptide's benefits tracked with activation of the Nrf2/HO-1 antioxidant pathway — reducing oxidative stress while restoring mitochondrial structure in the egg-supporting cells.

Why it matters beyond mice

Chemotherapy-induced ovarian damage is a major, under-addressed consequence of cancer treatment in young women. A mitochondria-targeted drug that is already through FDA approval for another indication is a far more credible candidate for repurposing than a brand-new compound.

The gap

Mice are not women. No human fertility data exists for SS-31, and ovarian biology differs meaningfully between species. This is a promising lead, not a treatment — but it's exactly the kind of repurposing lead worth watching.

Where the evidence stands

• Established: SS-31 received FDA accelerated approval as FORZINITY for Barth syndrome on September 19, 2025.
• Preliminary: All ovarian-protection findings come from a single mouse study.
• Contested: Whether Nrf2/HO-1 activation translates into human fertility preservation is untested.
• Absent: No human trial of SS-31 for chemotherapy-induced ovarian damage exists.